



Papilloplex® High Risk HPV



GeneFirst Papilloplex® HPV

Infection with human papillomavirus (HPV) poses a high risk for developing cervical cancer. The progression of cervical neoplasia to invasive cervical cancer can be either due to persistent HPV infections or expression of the viral *E6* and *E7* oncogenes. These oncogenes are active in cervical carcinomas and their corresponding proteins are directly involved in triggering cell proliferation, inhibition of apoptosis, reprogramming of differentiation, and chromosomal instability leading to malignant transformation of host cells. The Papilloplex® HR-HPV mRNA kit (detects E6/E7 mRNA) is designed to complement the Papilloplex® HR-HPV DNA kit to identify risk of cervical cancer in HPV positive individuals without the need to monitor for persistence of infection.



GeneFirst Papilloplex® HPV tests are designed for a true molecular HPV screening and triage testing strategy to support risk stratification of women infected with HPV

Proprietary Technology

Patented multiplex real-time PCR technology (MPA) for reliable results

Clinically Validated

Clinically validated under internationally recognised framework[†]

Robust Test Design

High sensitivity and specificity for detection of HPV DNA and RNA

Support Clinical Decision

Comprehensive information on genotyping, co-infection and biomarker presence to better risk-stratify patients

Innovative Approach

Dual test using the same sample (self-sample or clinician collected*)

Saves Time & Money

Helps reduce unnecessary colposcopies and cervical treatments

 $\hbox{*undergoing clinical validation for self-sampling}\\$

[†]VALGENT-4 available; currently undergoing clinical validation

Ordering Information

Catalogue Number	Product Name	Storage	Intended Use
MPAHPV004	Papilloplex® HR-HPV mRNA Kit	-20° C	CE-IVD
MPAHPV006	Papilloplex® HR-HPV DNA Kit	-20° C	CE-IVD

GeneFirst Ltd

Unit 2 The Quadrant Abingdon Science Park Abingdon, Oxfordshire OX14 3YS United Kingdom

